UT M.D. Anderson Cancer Center SPORE in Melanoma

德克萨斯大学医学博士的总体目标是安德森癌症中心皮肤癌孢子是 促进黑色素瘤预防、检测和治疗方面的创新研究， 消灭这种疾病。这个孢子将通过组装一个有才华的临床和 实验室科学家致力于将黑色素瘤的特异性发现从实验室翻译到 从诊所到实验室，从诊所到实验室。德克萨斯大学安德森癌症中心 作为优先事项之一，消除黑色素瘤这一健康风险，并为此目的， 1998年黑色素瘤多学科研究计划，以支持传统领域的培训和研究 为了推进黑色素瘤患者的治疗，有了这些支持，我们 我已经成功地组织了一个高效和富有成效的基础设施，这是本SPORE的框架 应用程序.我们现在正准备利用我们对黑色素瘤认识的快速增长 在分子和细胞水平上。 通过这个皮肤癌的孢子，我们将加强从研究中收集的见解的翻译 在黑色素瘤生物学和流行病学方面，我们致力于更有效的预防、检测和治疗方法。 这个皮肤癌的孢子提出了五个转化研究项目，三个职业发展职位 以及至少四个发展研究奖，都由三个核心（行政;信息学， 组织资源和病理学;和生物统计学）。这五个项目针对MHC-II呈递的黑素瘤 为CD 4细胞活化设计最佳免疫原性的肽（项目1）; DNA修复酶功能、遗传学和风险（项目2）：评估诱导型一氧化氮合酶作为 生存的预后因素和治疗信号级联的探索（项目3）; IL-8的调节 和MUC 18/MCAM联合常规化疗作为治疗方法（项目4）; 和评估特定的II类HLA等位基因作为生存的预后因素，以及评估 疾病进展中的相关细胞因子（项目5）。通过这项研究计划，并与充分 得克萨斯大学医学博士的支持安德森癌症中心，我们将作出重大影响， 预防和检测恶性黑色素瘤过程，以及治疗黑色素瘤患者。

The overall goal of this University of Texas M.D. Anderson Cancer Center SPORE in Skin Cancer is to facilitate innovative research in the prevention, detection and treatment of melanoma leading to the elimination of this disease. This SPORE will achieve this goal by assembling a talented group of clinical and laboratory scientists who are committed to the translation of findings specific for melanoma from the lab to the clinic as well as from the clinic to the laboratory. The University of Texas M.D. Anderson Cancer Center has made as one of its priorities the elimination of melanomas as a health risk, and to this end, established in 1998 a Multidisciplinary Research Program in Melanoma to support training and research across traditional administrative boundaries in order to advance treatment of patients with melanoma. With this support, we have successfully organized an efficient and productive infrastructure that is the framework for this SPORE application. We are now poised to take advantage of the rapid increases in our understanding of melanoma at the molecular and cellular levels. Through this SPORE in Skin Cancer, we will enhance the translation of insights gleaned from research in melanoma biology and epidemiology to more effective prevention, detection and treatment approaches. This SPORE in Skin Cancer proposes five translational research projects, three career development positions and at least four developmental research awards all being served by three cores (Administrative; Informatics, Tissue Resource, and Pathology; and Biostatistics). The five projects address MHC-II-presented melanoma peptides engineered for optimal immunogenicity for CD4 cell activation (Project 1); molecular epidemiology of DNA repair enzyme function, genetics, and risk (Project 2); evaluation of inducible nitric oxide synthase as a prognostic factor for survival and exploration of signaling cascades for therapy (Project 3); regulation of IL-8 and MUC18/MCAM in combination with conventional chemotherapy as therapeutic approaches (Project 4); and evaluation of specific class II HLA alleles as prognostic factors for survival and evaluation of the role of associated cytokines in disease progression (Project 5). Through this research program and with the full support of the University of Texas, M.D. Anderson Cancer Center, we will make significant impact toward the prevention and detection of malignant melanoma processes, and treatment of patients with melanoma.